東華大學圖書館 |

Global Landscape on Artemisinin and Its Derivatives: From Academia to Industry.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Global Landscape on Artemisinin and Its Derivatives: From Academia to Industry./
作者:	Liu, Kunmeng.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	156 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-02, Section: B.
Contained By:	Dissertations Abstracts International83-02B.
標題:	Biomedical engineering. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28548570
ISBN:	9798534654349

Global Landscape on Artemisinin and Its Derivatives: From Academia to Industry.
Liu, Kunmeng.

Global Landscape on Artemisinin and Its Derivatives: From Academia to Industry. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 156 p.

Source: Dissertations Abstracts International, Volume: 83-02, Section: B.

Thesis (Ph.D.)--University of Macau, 2021.

This item must not be sold to any third party vendors.

The remarkable story of the discovery of artemisinin and establishment of its antimalarial activity by Chinese scientists represents one of the great discoveries in medicine in the latter half of the 20th century. Traditional Chinese Medicine is a treasured natural resource of drug R&D. President Xi Jinping has promoted Traditional Chinese Medicine on many occasions. However, as the invention country of artemisinin, Chinese scientists did not apply for patent at the initial stage of R&D of artemisinin, and lost great markets of artemisinin. And the pharmaceutical industry has been facing significant challenges from several aspects, including decreasing R&D productivity, highly increasing R&D cost, advancing technological complexity, and great development uncertainty.The objective is to understand the global landscape of artemisinin in the context of the revival of natural small molecule drugs on the shift of R&D paradigm of traditional pharmaceutical industry, and this dissertation examine the scientific paper, patent publication, clinical trials and products of artemisinins over the past forty years, by descriptive analysis, bibliometric analysis, citation and collaboration network analysis. The results of academic work of scientific papers show that publication landscape of artemisinin is rapidly developing with main active regions of Western Europe, Southeast Asia and North America, including malaria endemic countries. A high intensity of alliances across the academia indicate the US is most active while China is underrepresented. The technologies of artemisinin derivatives based comination treatment, anticancer, medication safety, artemisinin resistance, and artemisinin synthesis have made unceasing progress in recent decades. Besides, IP activities of patents protection show that China and the US are mainly responsible for the dramatic increase of artemisinin patents over the last three decades. From the point of view of patents, remarkable technological issues on artemisinin are chemical and biological synthesis, novel combinations, new formulations and administration routes, drug repositioning, and minimizing the resistance. A critical challenge lies in how to stimulate the industry to develop artemisinin-related drugs by government regulation and public-private partnership. In addition, as for the clinical patterns, a significant number of clinical programs are promoted by technological advances by notable sponsorship of universities & research centers, though the final product are boosted by companies. Developed countries produce more products by clinical trials mostly conducted in African and Southeast Asian countries. These advances have also helped to diversify the therapeutic applications of artemisinin in cancers, COVID-19 and Systemic lupus erythematous. Concisely, cooperation mode changes from single academic sector to academic-industrial sector, when the technology transferring from academia to industry. Although many new indications have been explored through paper and patents, but its clinical application is very cautious, especially in the child and pregnant women. There is still a long way to go from basic research to clinical application.In conclusion, global artemisinin scientific paper activities clearly shows dynamic significances and continuously advancing relevant technologies. The IP strategy on global patents exhibits clear network properties with increasing scale. Clinical progress is involved in the improving field scale with exploration of new indications and follow with interest in specific population groups. Technology focus and partnership types vary along the drug development process.

ISBN: 9798534654349Subjects--Topical Terms:

535387
Biomedical engineering.
Subjects--Index Terms:

Bibliometric analysis

Global Landscape on Artemisinin and Its Derivatives: From Academia to Industry.
LDR:04905nmm a2200397 4500 001 2281477
005 20210920103013.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798534654349
035 $a (MiAaPQ)AAI28548570
035 $a AAI28548570
040 $a MiAaPQ $c MiAaPQ
100 1 $a Liu, Kunmeng. $3 3560129
245 1 0 $a Global Landscape on Artemisinin and Its Derivatives: From Academia to Industry.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 156 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-02, Section: B.
500 $a Advisor: Hu, Yuanjia.
502 $a Thesis (Ph.D.)--University of Macau, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a The remarkable story of the discovery of artemisinin and establishment of its antimalarial activity by Chinese scientists represents one of the great discoveries in medicine in the latter half of the 20th century. Traditional Chinese Medicine is a treasured natural resource of drug R&D. President Xi Jinping has promoted Traditional Chinese Medicine on many occasions. However, as the invention country of artemisinin, Chinese scientists did not apply for patent at the initial stage of R&D of artemisinin, and lost great markets of artemisinin. And the pharmaceutical industry has been facing significant challenges from several aspects, including decreasing R&D productivity, highly increasing R&D cost, advancing technological complexity, and great development uncertainty.The objective is to understand the global landscape of artemisinin in the context of the revival of natural small molecule drugs on the shift of R&D paradigm of traditional pharmaceutical industry, and this dissertation examine the scientific paper, patent publication, clinical trials and products of artemisinins over the past forty years, by descriptive analysis, bibliometric analysis, citation and collaboration network analysis. The results of academic work of scientific papers show that publication landscape of artemisinin is rapidly developing with main active regions of Western Europe, Southeast Asia and North America, including malaria endemic countries. A high intensity of alliances across the academia indicate the US is most active while China is underrepresented. The technologies of artemisinin derivatives based comination treatment, anticancer, medication safety, artemisinin resistance, and artemisinin synthesis have made unceasing progress in recent decades. Besides, IP activities of patents protection show that China and the US are mainly responsible for the dramatic increase of artemisinin patents over the last three decades. From the point of view of patents, remarkable technological issues on artemisinin are chemical and biological synthesis, novel combinations, new formulations and administration routes, drug repositioning, and minimizing the resistance. A critical challenge lies in how to stimulate the industry to develop artemisinin-related drugs by government regulation and public-private partnership. In addition, as for the clinical patterns, a significant number of clinical programs are promoted by technological advances by notable sponsorship of universities & research centers, though the final product are boosted by companies. Developed countries produce more products by clinical trials mostly conducted in African and Southeast Asian countries. These advances have also helped to diversify the therapeutic applications of artemisinin in cancers, COVID-19 and Systemic lupus erythematous. Concisely, cooperation mode changes from single academic sector to academic-industrial sector, when the technology transferring from academia to industry. Although many new indications have been explored through paper and patents, but its clinical application is very cautious, especially in the child and pregnant women. There is still a long way to go from basic research to clinical application.In conclusion, global artemisinin scientific paper activities clearly shows dynamic significances and continuously advancing relevant technologies. The IP strategy on global patents exhibits clear network properties with increasing scale. Clinical progress is involved in the improving field scale with exploration of new indications and follow with interest in specific population groups. Technology focus and partnership types vary along the drug development process.
590 $a School code: 1382.
650 4 $a Biomedical engineering. $3 535387
650 4 $a Pharmacology. $3 634543
650 4 $a Research methodology. $3 3559994
650 4 $a Collaboration. $3 3556296
650 4 $a Science. $3 516376
650 4 $a Trends. $3 3560051
650 4 $a Inventors. $3 534219
650 4 $a Dissertations & theses. $3 3560115
650 4 $a Databases. $3 747532
650 4 $a Chinese medicine. $3 3560131
653 $a Bibliometric analysis
653 $a Clinical trials
653 $a Social network analysis
653 $a Research and development
653 $a Development
653 $a Patent
690 $a 0541
690 $a 0419
690 $a 0505
690 $a 0429
710 2 $a University of Macau. $b Chinese Medical Sciences. $3 3560130
773 0 $t Dissertations Abstracts International $g 83-02B.
790 $a 1382
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28548570